Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.39 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.35 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.35 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17518370 | 0.82 | TRPV1 (0.34) | SPHK1 | |
| SCHEMBL4744405 | 0.82 | GPR84 (0.52) | CA2GPR84MAPK1FFAR1 | |
| SCHEMBL667414 | 0.82 | GPR84 (0.52) | CA2GPR84MAPK1FFAR1 | |
| SCHEMBL17518256 | 0.81 | GABRP (0.41) | FFAR1 | |
| SCHEMBL17920247 | 0.79 | GABRR1 (0.41) | — | |
| SCHEMBL17518366 | 0.79 | GABRP (0.32) | — | |
| SCHEMBL15810294 | 0.78 | ECE1 (0.33) | — | |
| SCHEMBL17524660 | 0.78 | ALDH1A1 (0.33) | — | |
| SCHEMBL17518381 | 0.78 | LMNA (0.48) | — | |
| SCHEMBL17524656 | 0.78 | SIGMAR1 (0.36) | SPHK1GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019016572-A1 | CYCLOSPORIN ANALOGUES AND USES THEREOF | CYPRALIS LTD (GB) | 2019-01-24 | — | — | WO | disclosed |
| US-20170101445-A1 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION | S&T GLOBAL INC. | 2017-04-13 | — | — | US | disclosed |
| US-20170029469-A1 | CYCLOSPORIN ANALOGS | ALLERGAN, INC. | 2017-02-02 | — | — | US | disclosed |
| US-9493511-B2 | Cyclosporin analogs | ALLERGAN, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20160039879-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL INC. (US) | 2016-02-11 | — | — | US | disclosed |
| US-20150065433-A1 | CYCLOSPORIN ANALOGS | ALLERGAN, INC. (US) | 2015-03-05 | — | — | US | disclosed |
| US-20130210704-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL INC. (US) | 2013-08-15 | — | — | US | disclosed |
| WO-2012075494-A1 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION | S&T GLOBAL INC. (US) | 2012-06-07 | — | — | WO | disclosed |
| US-20120088734-A1 | Cyclosporin Analogs | ALLERGAN, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| WO-2012021796-A2 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION | S&T GLOBAL, INC. (US) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065433-A1 | CYCLOSPORIN ANALOGS | CHP1, TSLP, PPP3R1 | CA2 2370/4885CA1 4455/4885SPHK1 273/4885 |
| US-20120088734-A1 | Cyclosporin Analogs | CHP1, TSLP, PPP3R1 | CA2 2370/4885CA1 4455/4885SPHK1 273/4885 |
| US-20170029469-A1 | CYCLOSPORIN ANALOGS | CHP1, TSLP, PPP3R1 | CA2 2370/4885CA1 4455/4885SPHK1 273/4885 |
| US-20130210704-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | FKBP1B, MALT1, FKBP5 | CA2 1053/4885CA1 4107/4885SPHK1 660/4885 |
| US-20160039879-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | FKBP1B, MALT1, FKBP5 | CA2 1053/4885CA1 4107/4885SPHK1 660/4885 |
| US-20170101445-A1 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION | HAVCR2, TSLP, HLA-DRB1 | CA2 1103/4885CA1 2992/4885SPHK1 1370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.